2018
DOI: 10.1002/ddr.21465
|View full text |Cite
|
Sign up to set email alerts
|

Reaching toward underexplored targets in antibacterial drug design

Abstract: The increase of antimicrobial resistance necessitates the renewal and strong research involvement in antibacterial drug design. In the following work, we comment on the key approaches used in development of new antibacterials, focusing on intracellular therapeutic targets that have been so far mostly underexplored: the enzymes of the Mur pathway MurA to MurF. We identify common obstacles observed during research on MurA, MurB, and Mur ligases inhibitors and their development into potential antibacterial compou… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
24
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
6

Relationship

1
5

Authors

Journals

citations
Cited by 29 publications
(27 citation statements)
references
References 48 publications
(72 reference statements)
0
24
0
Order By: Relevance
“…MurF catalyzes the last step of the cytoplasmic phase of peptidoglycan biosynthesis which is crucial to bacterial cell wall synthesis . This is an ATP‐dependent reaction utilizing d ‐ala‐ d ‐ala and UDP‐ N ‐acetyl‐muramoyl‐Ala‐ d ‐Glu‐ l ‐Lys to form UDP‐ N ‐acetyl‐ d ‐muramoyl‐ l ‐Ala‐ d ‐Glu‐ l ‐Lys‐ d ‐Ala‐ d ‐Ala (UDP‐ N ‐acetylmuramate‐pentapeptide) . Only one inhibitor, fosfomycin, has been clinically used as an effective antibiotic MurA inhibitor.…”
Section: Resultsmentioning
confidence: 99%
See 3 more Smart Citations
“…MurF catalyzes the last step of the cytoplasmic phase of peptidoglycan biosynthesis which is crucial to bacterial cell wall synthesis . This is an ATP‐dependent reaction utilizing d ‐ala‐ d ‐ala and UDP‐ N ‐acetyl‐muramoyl‐Ala‐ d ‐Glu‐ l ‐Lys to form UDP‐ N ‐acetyl‐ d ‐muramoyl‐ l ‐Ala‐ d ‐Glu‐ l ‐Lys‐ d ‐Ala‐ d ‐Ala (UDP‐ N ‐acetylmuramate‐pentapeptide) . Only one inhibitor, fosfomycin, has been clinically used as an effective antibiotic MurA inhibitor.…”
Section: Resultsmentioning
confidence: 99%
“…UDP‐ N ‐acetylmuramate—alanine ligase (MurC) facilitates the first ATP‐dependent peptide addition to UDP‐ N ‐acetylmuramate starting the peptide chain of UDP‐ N ‐acetylmuramate‐pentapeptide . Similar to MurF, several inhibitors of the MurC have been reported; however, little show effective antibacterial activity aside from inhibitors with an N ‐acylhydrazone scaffold that had dual inhibitory activity with MurC and MurD …”
Section: Resultsmentioning
confidence: 99%
See 2 more Smart Citations
“…Previously, an in silico study stated that metabolic pathway proteins of Ott may act as probable target for drug discovery process (Sharma et al, 2018b). It is a well-established fact that Mur enzymes are involved in biosynthesis of bacterial cell wall using divalent metal ions as cofactor and are best intracellular therapeutic targets (Munshi et al, 2013; Moraes et al, 2015; Jukič et al, 2019). DDI enzyme uses Mg 2+ ion as cofactor and catalyzes early steps of peptidoglycan synthesis, i.e., formation of D-Ala-D-Ala and D-Ala-D-Ser dipeptides in bacteria (Tytgat et al, 2009).…”
Section: Resultsmentioning
confidence: 99%